Merck (MRK), Pfizer (PFE) Lilly (LLY) Shares Decline Amid Biotech Weakness
Tweet
Share
E-mail
Get Alerts MRK Hot Sheet
Price: $149.28 --0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +0.2%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +0.2%
Join SI Premium – FREE
Merck (NYSE: MRK), Pfizer (NYSE: PFE) Lilly (NYSE: LLY) Shares Decline Amid Biotech Weakness
- Merck -2.2%
- Pfizer -1.8
- Lilly -2.5%
- ETF IBB -2.4%
- ETF XBI -3.3%
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen on Merck (MRK): 'We like this deal'
- Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
- Boeing wins $20B U.S. Navy contract for sixth-generation fighter jet
Create E-mail Alert Related Categories
ETFs, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
